Anderson Gaweco, M.D., Ph.D.

Chief Executive Officer

Dr. Gaweco is the Founder and CEO of Innovimmune Biotherapeutics. He was previously Chief Medical Officer and Chief Scientific Officer of Apeiron Biologics, Chief Medical Officer of Veloxis Pharmaceuticals (Lifecycle Pharma), Global Clinical Science Leader at Roche, Early Clinical Leader at Pfizer and Senior Medical Scientist at AstraZeneca. With increasing global leadership responsibilities in public and private life science companies, he led the worldwide discovery, clinical development and commercialization of small molecule, biologic, RNA and cell therapy NME candidates from Lead Discovery through Clinical Development & Product Launches in the Immuno-Oncology, Autoimmune Disease, Inflammation and Virology therapeutic areas. His successful track-record in Global Drug Development includes leadership roles in advancing several NMEs (NCE, NBE, RNA, cell therapy) against novel therapeutic targets: Xeljanz [CP-690,550] (the first JAK inhibitor successfully developed; 2003 Science), retinoic acid receptor-related orphan receptor [ROR] & T helper 17 [Th17] cell modulators, Nuclear hormone receptors, selective integrin α4/β7 antagonists, macrophage migration inhibitory factor [MIF] inhibitors, anti-CD20, anti-CD25/anti-IL-2R, Pegasys, Prograf, Nexium and Crestor. As Chair of the Xeljanz Early Clinical Team, Dr. Gaweco and his team members were honored with the Pfizer Early Clinical Management Team of the Year Award in 2003. He has served as member of the Clinical Research Advisory Council (2003-2008) and Training & Workforce (2004-2007) Committees of the American Society of Transplantation. Before joining the industry, Dr. Gaweco held dual faculty appointments as Assistant Professor of Medicine at the Division of Gastroenterology & Hepatology, Department of Medicine & Assistant Professor of Pathology at the Department of Pathology at Loyola University Medical Center in Chicago.

Dr. Gaweco received his M.D. and Ph.D. magna cum laude in Immunology and was trained in Pathology at the Ruprecht-Karls-Universität Heidelberg, Germany. He has completed management trainings in Executive Leadership Development at London Business School and Biomedical Research at Harvard School of Public Health. He was a recipient of the United Kingdom's Overseas Research Scholarships (ORS) award for the University of Oxford (Oriel College & Nuffield Department of Surgery under Professor Sir Peter J. Morris) and numerous Young Investigator & Scientist awards from various international professional medical societies for his academic research in Immunology, Inflammation and Immunomodulation. Dr. Gaweco has authored over 100+ peer-reviewed journal articles (including Science), book chapters, abstracts and conference proceedings; and inventor of 20+ worldwide patent filings of immunomodulatory drugs for Autoimmune Diseases, Inflammation and Cancer. He held academic faculty appointments as Visiting Professor at the State University of New York Downstate Medical Center (2012-2016), Guest Faculty at the Georgetown University Biotechnology Program (2012-2020) & Adjunct Professor at Georgetown University Medical Center, Georgetown University School of Medicine (2017-2020).